Drugs / Omega Three Polyunsaturated fatty acids
Omega Three Polyunsaturated fatty acids
also known as
Lovaza, Omega three polyunsaturate ethyl esters
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT00446966 | Feb 2007 → Dec 2009 | atrial fibrillation | Chirag Sandesara | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Omega Three Polyunsaturated fatty acids | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00446966 ↗ |
| Known as | Lovaza, Omega three polyunsaturate ethyl esters | “Lovaza, Omega three polyunsaturate ethyl esters” NCT00446966 ↗ |
| Route | Oral | “2 grams orally twice daily pre-operatively and 2 grams orally daily after until primary endpoint or 14 days.” NCT00446966 ↗ |